 |
  |
Kevin R. Sweeney
Practice Area Chair
Andrew T. Hoyne
Practice Area Vice Chair
Ari M. Bai
Ryan A. Berry
Mary Beth Blake
Teresa A Brooks
Yu Cai, Ph.D.
Elton F. Dean III
Kathryn J. Doty
Erik R. Edwards
Frederic J. Entin
Robert O. Enyard Jr.
Anita R. Estell
Geoffrey D. Fasel
Todd S. Hofmeister, Ph.D.
Curtis M. Holland
Quentin L. Jennings
Paul A. Jenny
Timothy J. Keefer
J. Morgan Kirley
Gregory M. Kratofil, Jr.
Christine Meis McAuliffe
Jane K. McCahill
Cortney Lang Mendenhall
Tara A. Nealey, Ph.D.
S. Patrick O'Bryan
Alan K. Parver
Jay E. Pietig
Andrea M. Porterfield
William E. Quick
Rebecca C. Riley-Vargas,
Ph.D.
Mark A. Salle
Jason W. Sapsin
Thomas J. Schenkelberg
Kelley A. Schnieders
Teddy C. Scott, Ph.D.
Timothy D. Steffens
James M. Stipek
Steven K. Stranne, M.D.
Kelly Sullivan-Deady
Tracey S. Truitt
Brian G. Wallace
Michael A. Williamson
Patrick C. Woolley
To learn more about
our
Life Sciences
group,
click here
|
|
 |
| |
| |
November 2010
|
A Polsinelli Shughart Life Sciences e-Alert |
Qualifying Therapeutic Discovery Project Awards Announced |
| |
On November 1, the Treasury Department began announcing the recipients of awards under the Qualifying Therapeutic Discovery Project Tax Credit Program, which authorized up to $1 billion in tax credits or grants to biopharmaceutical companies with 250 or fewer employees. The awards cover up to 50 percent of the costs incurred in 2009 and incurred or expected to be incurred in 2010 in developing therapies to prevent, treat or diagnose a variety of diseases and conditions. In some cases, applicants were selected to receive awards for multiple projects. Awards of approximately $250,000 were made to most of the approximately 4,000 projects nationwide that were approved to receive grants.
“This was a very competitive grant process to implement a unique program intended to jump start the growth of the life science industry,” said Polsinelli Shughart Life Sciences Chair Kevin R. Sweeney. “A number of our clients were successful in receiving grants, and we congratulate them on moving quickly once the details of the program were announced. We applaud their dedication to the life sciences industry and to furthering the development of new therapies and treatments that will improve the overall quality of life.”
For More Information
If you have questions or need further comment, please contact:
|
Polsinelli Shughart | In the News |
Headlines and Bylines from polsinelli.com |
| |
|
 |
| |
|
About Polsinelli Shughart PC
With more than 500 attorneys, Polsinelli Shughart PC is a national law firm that is a recognized leader in the areas of business law, financial services, real estate and business litigation. Serving corporate, institutional and individual clients, Polsinelli Shughart is redefining the business of law by sharing ideas, goals and outcomes with its clients. The firm builds enduring relationships by creating value beyond legal services – with passion, ingenuity and a sense of urgency. The firm can be found online at www.polsinelli.com.
|
| |
| |
|
 |
To update your email preferences, please contact Therese O'Shea. To opt out of these communications, click the unsubscribe link below.
Polsinelli Shughart PC provides this material for informational purposes only. The material provided herein is general and is not intended to be legal advice. Nothing herein should be relied upon or used without consulting a lawyer to consider your specific circumstances, possible changes to applicable laws, rules and regulations and other legal issues. Receipt of this material does not establish an attorney-client relationship.
Polsinelli Shughart is very proud of the results we obtain for our clients, but you should know that past results do not guarantee future results; that every case is different and must be judged on its own merits; and that the choice of a lawyer is an important decision and should not be based solely upon advertisements.
Polsinelli Shughart® is a registered trademark of Polsinelli Shughart PC.
|
 |
Copyright © 2010 Polsinelli Shughart PC ®. |
| |
|
